



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## Supplementary Materials

### **Mechanism of the dual activities of CYP17A1 and binding to anti-prostate cancer drug abiraterone revealed by a novel V366M mutation causing 17,20 lyase deficiency.**

Mónica Fernández-Cancio<sup>1†</sup>, Núria Camats<sup>1,2,3†</sup>, Christa E Flück<sup>2,3,†</sup>, Adam Zalewski<sup>2,3,†</sup>, Bernhard Dick<sup>4</sup>, Brigitte M Frey<sup>4</sup>, Raquel Monné<sup>5</sup>, Núria Torán<sup>6</sup>, Laura Audí<sup>1</sup>, and Amit V Pandey<sup>2,3\*</sup>

<sup>1</sup>Growth and Development Research Unit, Vall d’Hebron Research Institute (VHIR), Center for Biomedical Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Autonomous University of Barcelona, Barcelona, Spain

<sup>2</sup>Pediatric Endocrinology Unit, Department of Paediatrics, University Children’s Hospital Bern,

<sup>3</sup>Department of Biomedical Research, University of Bern, Bern, Switzerland.


<sup>4</sup>Department of Nephrology and Hypertension, University of Bern, Bern, Switzerland.

<sup>5</sup>Pediatric Service, Hospital Joan XXIII, Tarragona, Spain.

<sup>6</sup>Pathology Department, Hospital Universitari Vall d’Hebron, CIBERER, Barcelona, Spain.


<sup>†</sup>Co-first authors.

\* Correspondence: amit@pandeylab.org; Tel.: +41-31-632-9637



22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32

**Supplementary Fig. 1:** Details of abiraterone interaction with the WT and V366M variant of CYP17A1. In the WT CYP17A1 abiraterone binds by forming a nitrogen-iron coordination with the central heme (a and c). In the V366M mutant, the larger methionine side chain protrudes towards the heme iron and creates a steric hindrance for the binding of abiraterone (b and d). As a result, abiraterone is ineffective towards the residual 17hydroxylation reaction of the mutant enzyme. Panels a and b show the ribbons diagram of the active site of CYP17A1 while panels c and d show the ligand interactions depicted by LIGPLOT analysis.



33

34 **Supplementary Fig. 2:** Details of 17OH-PREG interaction with the V366M variant of  
 35 CYP17A1. There are differences in optimal binding poses for PREG/PROG and 17OH-PREG  
 36 and while interaction with N202 seems to benefit in orienting the steroids for 17hydroxylase  
 37 reaction, this increases the distance between C17 and heme iron. The multiple additional  
 38 interactions observed here for 17OH-PREG and V366M mutant of CYP17A1 indicate  
 39 nonoptimal binding and explain the loss of 17,20 lyase activity.

40

41

42

43

44

45